Queensland’s $181 million sovereign industry fund is backing projects manufacturing cancer treatment therapies and the state’s first semi-automated sterile fill and finish platform in its initial biomedicine investments announced on Saturday.
An AdvanCell project secured $15 million for its project to commercially manufacture Thorium-228, the critical upstream isotope in targeted alpha therapies that can selectively destroy cancer cells.
The targeted approach has shown fewer side effects compared to traditional cancer …
Want to know how this story ends?
Become a subscriber for complete access to all stories on InnovationAus.com and our daily newsletter.
Already a member? Log in here
Do you know more? Contact James Riley via Email.